{"id":379215,"date":"2020-11-12T02:03:52","date_gmt":"2020-11-12T07:03:52","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379215"},"modified":"2020-11-12T02:03:52","modified_gmt":"2020-11-12T07:03:52","slug":"cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/","title":{"rendered":"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">MONMOUTH JUNCTION, N.J.<\/span>, <span class=\"xn-chron\">Nov. 12, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2149810168&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" rel=\"nofollow noopener noreferrer\">CytoSorbents Corporation<\/a><\/u>\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2548675957&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener noreferrer\">CytoSorb\u00ae<\/a>\u00a0blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on\u00a0Tuesday, November 17, 2020 and meet with investors in 1&#215;1 meetings throughout the day.\u00a0 For European investors, please contact your Jefferies representative to assist with scheduling.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" title=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.  CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto\/CytoSorbents Corporation)\" alt=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.  CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto\/CytoSorbents Corporation)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <u><br \/>\n            <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=640906495&amp;u=https%3A%2F%2Fwww.jefferies.com%2FIdeasAndPerspectives%2FConferences%2F325%2F111720&amp;a=Jefferies+Virtual+London+Healthcare+Conference+\" rel=\"nofollow noopener noreferrer\">Jefferies Virtual London Healthcare Conference <\/a><br \/>\n          <\/u><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <br \/>When:<\/b>\u00a0Tuesday, November 17, 2020 from\u00a02:40PM-<span class=\"xn-chron\">3:10PM GMT<\/span> (<span class=\"xn-chron\">9:40AM-10:10AM EST<\/span>)<b><u><br \/><\/u><\/b><b>Webcast: <\/b><b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=1211026896&amp;u=https%3A%2F%2Fwsw.com%2Fwebcast%2Fjeff141%2Fctso%2F1859625&amp;a=Jefferies+London+Presentation+Webcast+Link+\" rel=\"nofollow noopener noreferrer\">Jefferies London Presentation Webcast Link <\/a><\/b><\/p>\n<p>A live webcast of the presentation will be available at the above webcast link.\u00a0 An archived replay of the webcast will be available for 90 days following the event.<\/p>\n<p>\n        <b>About CytoSorbents Corporation (<\/b><br \/>\n        <b>NASDAQ:\u00a0CTSO<\/b><br \/>\n        <b>)<\/b>\n      <\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=1281125230&amp;u=https%3A%2F%2Fcytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" rel=\"nofollow noopener noreferrer\">CytoSorbents Corporation<\/a>\u00a0is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2548675957&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener noreferrer\">CytoSorb\u00ae<\/a> is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2548675957&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener noreferrer\">CytoSorb\u00ae<\/a> is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb\u00ae has been used in more than 110,000 human treatments to date.\u00a0 CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery.\u00a0 CytoSorb has also received FDA Emergency Use Authorization in <span class=\"xn-location\">the United States<\/span> for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.\u00a0 CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.<\/p>\n<p>CytoSorbents&#8217; purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than <span class=\"xn-money\">$38 million<\/span> from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF\/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY\u2122, CytoSorb-XL\u2122, HemoDefend-RGC\u2122, HemoDefend-BGA\u2122, VetResQ\u2122, K<sup>+<\/sup>ontrol\u2122, ContrastSorb, DrugSorb, and others.\u00a0 \u00a0\u00a0For more information, please visit the Company&#8217;s websites at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=142110414&amp;u=https%3A%2F%2Fcytosorbents.com%2F&amp;a=www.cytosorbents.com\" rel=\"nofollow noopener noreferrer\">www.cytosorbents.com<\/a> and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2016157665&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=www.cytosorb.com\" rel=\"nofollow noopener noreferrer\">www.cytosorb.com<\/a> or follow us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2531567233&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents&amp;a=Facebook\" rel=\"nofollow noopener noreferrer\">Facebook<\/a> and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=1930609676&amp;u=https%3A%2F%2Ftwitter.com%2FCytoSorbents&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions,\u00a0including statements regarding our expectations about our cash runway, the advancement of our trials, our plans to initiate new trials, our goals to develop and commercialize CytoSorb and the timing thereof, the potential impact of COVID-19 on our operations and milestones,\u00a0 and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on <span class=\"xn-chron\">March 5, 2020<\/span>, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n<p>\n        <b>Please Click to Follow Us on <\/b><br \/>\n        <b><br \/>\n          <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=2531567233&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents&amp;a=Facebook\" rel=\"nofollow noopener noreferrer\">Facebook<\/a><br \/>\n        <\/b><br \/>\n        <b>\u00a0and <\/b><br \/>\n        <b><br \/>\n          <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979611-1&amp;h=1930609676&amp;u=https%3A%2F%2Ftwitter.com%2FCytoSorbents&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Cytosorbents Contact: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Amy Vogel<\/span><br \/>\n        <br \/>Investor Relations <br \/>732-398-5394 <br \/><a target=\"_blank\" href=\"mailto:avogel@cytosorbents.com\" rel=\"nofollow noopener noreferrer\">avogel@cytosorbents.com<\/a><\/p>\n<p>\n        <b>Investor Relations Contact: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Jeremy Feffer<\/span><br \/>\n        <br \/>LifeSci Advisors <br \/>917-749-1494 <br \/><a target=\"_blank\" href=\"mailto:jeremy@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\">jeremy@lifesciadvisors.com<\/a><\/p>\n<p>\n        <b>Public Relations Contact: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Eric Kim<\/span><br \/>\n        <br \/>Rubenstein Public Relations <br \/>212-805-3055 <br \/><a target=\"_blank\" href=\"mailto:ekim@rubensteinpr.com\" rel=\"nofollow noopener noreferrer\">ekim@rubensteinpr.com<\/a><\/p>\n<p>\n        <b \/>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY89506&amp;sd=2020-11-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference-301171575.html\">http:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference-301171575.html<\/a><\/p>\n<p>SOURCE  CytoSorbents Corporation<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY89506&amp;Transmission_Id=202011120200PR_NEWS_USPR_____NY89506&amp;DateId=20201112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire MONMOUTH JUNCTION, N.J., Nov. 12, 2020 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb\u00ae\u00a0blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on\u00a0Tuesday, November 17, 2020 and meet with investors in 1&#215;1 meetings throughout the day.\u00a0 For European investors, please contact your Jefferies representative to assist with scheduling. Jefferies Virtual London Healthcare Conference When:\u00a0Tuesday, November 17, 2020 from\u00a02:40PM-3:10PM GMT (9:40AM-10:10AM EST)Webcast: Jefferies London Presentation Webcast Link A live webcast of the presentation will be available at the above webcast link.\u00a0 An archived replay of the webcast will be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379215","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MONMOUTH JUNCTION, N.J., Nov. 12, 2020 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb\u00ae\u00a0blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on\u00a0Tuesday, November 17, 2020 and meet with investors in 1&#215;1 meetings throughout the day.\u00a0 For European investors, please contact your Jefferies representative to assist with scheduling. Jefferies Virtual London Healthcare Conference When:\u00a0Tuesday, November 17, 2020 from\u00a02:40PM-3:10PM GMT (9:40AM-10:10AM EST)Webcast: Jefferies London Presentation Webcast Link A live webcast of the presentation will be available at the above webcast link.\u00a0 An archived replay of the webcast will be available &hellip; Continue reading &quot;CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T07:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference\",\"datePublished\":\"2020-11-12T07:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"wordCount\":857,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/\",\"name\":\"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"datePublished\":\"2020-11-12T07:03:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference - Market Newsdesk","og_description":"PR Newswire MONMOUTH JUNCTION, N.J., Nov. 12, 2020 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb\u00ae\u00a0blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on\u00a0Tuesday, November 17, 2020 and meet with investors in 1&#215;1 meetings throughout the day.\u00a0 For European investors, please contact your Jefferies representative to assist with scheduling. Jefferies Virtual London Healthcare Conference When:\u00a0Tuesday, November 17, 2020 from\u00a02:40PM-3:10PM GMT (9:40AM-10:10AM EST)Webcast: Jefferies London Presentation Webcast Link A live webcast of the presentation will be available at the above webcast link.\u00a0 An archived replay of the webcast will be available &hellip; Continue reading \"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T07:03:52+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference","datePublished":"2020-11-12T07:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/"},"wordCount":857,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/","name":"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","datePublished":"2020-11-12T07:03:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-present-at-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379215"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}